Pi-Cardia

Executive Summary

Pi-Cardia is an Israeli med-tech company developing catheter-based, non-implant leaflet modification devices for structural heart disease. Its two lead products address critical unmet needs in transcatheter aortic and mitral valve interventions. The ShortCut device is designed to split bioprosthetic valve leaflets, preventing coronary obstruction during valve-in-valve TAVR, a potentially fatal complication. The Leaflex Performer mechanically scores calcified aortic leaflets to restore leaflet mobility, offering an alternative to valve replacement in certain patients. Both devices target high-risk populations and aim to expand the treatable patient pool by providing less invasive options. Founded in 2020, the company is currently in the preclinical stage and has not yet raised disclosed funding or generated revenue. The innovative approach and clear clinical rationale position Pi-Cardia as an attractive early-stage investment opportunity, though significant development and regulatory milestones remain ahead.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical study initiation for ShortCut or Leaflex Performer50% success
• Q3 2026Series A funding round completion70% success
• Q4 2026FDA IDE approval for early feasibility study60% success